TABLE 2.
Parameter estimates of the final model and bootstrap validation.
| Parameter | Estimate | SE (%) | Bootstrap | Bias (%) | |
|---|---|---|---|---|---|
| Median | 95% confidence interval | ||||
| CL/F (L/h) | 19.8 | 7.0 | 19.8 | [16.5, 23.7] | 0 |
| V/F (102L) | 113 | 13.9 | 114 | [85, 148] | 0.885 |
| Ka (h−1) | 4.48 (fixed) | — | — | — | — |
| θPOS | −0.57 | 12.1 | −0.58 | [−0.73, −0.26] | 1.754 |
| ωCL/F | 0.349 | 15.8 | 0.339 | [0.131, 0.539] | −2.865 |
| ωV/F | 0.859 | 14.7 | 0.831 | [0.501, 1.077] | −3.260 |
| σ1 | 0.259 | 11.8 | 0.258 | [0.169, 0.314] | −0.386 |
| σ2 | 1.353 | 13.2 | 1.356 | [0.966, 1.723] | 0.222 |
The 95% confidential interval was displayed as the 2.5th and 97.5th percentiles of bootstrap estimates. CL/F, apparent oral clearance (L/h); V/F, apparent volume of distribution (L); Ka, absorption rate constant (h−1); θPOS, was the coefficient of the posaconazole; ωCL/F, interindividual variability of CL/F; ωV/F, interindividual variability of V/F; σ1, residual variability, proportional error; σ2, residual variability, additive error; bias, prediction error, bias = (median-estimate)/estimate×100%.